Marijuana-Based Drug Nears Approval for Childhood Epilepsy
On September 26, a marijuana-based childhood epilepsy drug took a step closer to winning approval when its maker announced promising phase 3 clinical trial results. [1]
Justin Gover, CEO of the British biotech company GW Pharmaceuticals, said that the children participating in the trial had previously tried 10 other anti-epileptic drugs. Despite using the medication, the young participants still experienced 3 seizures a day, approximately 90 a month. Said Gover:
